Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome

Gynecologic and Obstetric Investigation

Volumn 58, Issue 1, 2004, Pages 36-41

  Vrbikova J ^a   Hill, M ^a   Dvorakova K ^a   Stanicka S ^a   Vondra, K ^a   Starka L ^a  

^a INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

Androgen; Flutamide; Insulin resistance; Polycystic ovary

Indexed keywords

ANDROSTENEDIONE; APO FLUTAMIDE; CORTICOTROPIN; FLUTAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; TESTOSTERONE 17BETA DEHYDROGENASE; TRIACYLGLYCEROL;

ADRENAL GLAND; ADULT; ANDROGEN SYNTHESIS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID BLOOD LEVEL; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEROIDOGENESIS;

17-HYDROXYSTEROID DEHYDROGENASES; ADRENAL GLANDS; ADRENOCORTICOTROPIC HORMONE; ADULT; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENEDIONE; BODY MASS INDEX; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FEMALE; FLUTAMIDE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; OBESITY; POLYCYSTIC OVARY SYNDROME; STEROIDS; TESTOSTERONE;

EID: 4344635558     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077827     Document Type: Article

References (28)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI: A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
2. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998;83:3078-3082.
3. Stanczyk FZ, Chang L, Carmina E, Putz Z, Lobo RA: Is 11β- hydroxyandrostenedione a better marker of adrenal androgen excess than dehydroepiandrosterone sulfate? Am J Obstet Gynecol 1991;165:1837-1842.
4. Ehrmann DA, Barnes RB, Rosenfield RL: Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 1995;16:322-353.
5. Ayub M, Levell M J: Inhibition of rat testicular 17α-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU-23908, cyproterone acetate) in vitro. J Steroid Biochem 1987;28:43-47.
6. Belanger B, Caron S, Boudou P, Fiet J, Belanger A: Adrenal steroidogenesis in the guinea pig: Effects of androgens. Steroids 1992;57:76-81.
7. Laue L, Merke DP, Jones JV, Barnes KM, Hill S, Cutler GB Jr: A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996;81:3535-3539.
8. Charmandari E, Calis KA, Keil MF, Mohassel MR, Remaley A, Merke DP: Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2002;87:3197-3200.
9. Muderris II, Bayram F, Sahin Y, Kelestimur F: A comparison between two doses of flutamide (250 and 500 mg/day) in the treatment of hirsutism. Fertil Steril 1997;68:644-647.
10. Muderris II, Bayram F: Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. J Endocrinol Invest 1999;22:165-168.
11. Diamanti-Kandarakis E, Mitrakou A, Hennes MM, Platanissiotis D, Kaklas N, Spina J, Georgiadou E, Hoffmann RG, Kissebah AH, Raptis S: Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism 1995;44:525-531.
12. De Leo V, la Marca A, Lanzetta D, Cariello PL, D'Antona D, Morgante G: Effects of flutamide on pituitary and adrenal responsiveness to corticotrophin releasing factor. Clin Endocrinol (Oxf) 1998;49:85-89.
13. Ibanez L, Potau N, Marcos MV, de Zegher F: Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide. J Clin Endocrinol Metab 2000;85:3251-3255.
14. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952-960.
15. Ibanez L, Valls C, Ferrer A, Ong K, Dunger DB, De Zegher F: Additive effects of insulinsensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 2002;87:2870-2874.
16. Dodin S, Faure N, Cedrin I, Mechain C, Turcot-Lemay L, Guy J, Lemay A: Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol (Oxf) 1995;43:575-582.
17. Fruzzetti F, De Lorenzo D, Ricci C, Fioretti P: Clinical and endocrine effects of flutamide in hyperandrogenic women. Fertil Steril 1993;60:806-813.
18. Taylor AE: Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications. Am J Obstet Gynecol 1998;179:S94-S100.
19. Wild RA: Polycystic ovary syndrome: A risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35-43.
20. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ: The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2699-2705.
21. Dunaif A: Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
22. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
23. Young RP, Critchley JA, Anderson PJ, Lau MS, Lee KK, Chan JC: The short insulin tolerance test: Feasibility study using venous sampling. Diabet Med 1996;13:429-433.
24. Larsson H, Ahren B: Glucose-dependent arginine stimulation test for characterization of islet function: Studies on reproducibility and priming effect of arginine. Diabetologia 1998;41:772-777.
25. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
26. Azziz R, Bradley EL Jr, Potter HD, Boots LR: Adrenal androgen excess in women: Lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. J Clin Endocrinol Metab 1995;80:400-405.
27. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G: Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99-102.
28. Fukushima DK, Levin J, Kream J, Freed SZ, Whitmore WF, Hellman L, Zumoff B: Effect of flutamide on cortisol metabolism. J Clin Endocrinol Metab 1978;47:788-791.